Bioventix plc
(“Bioventix” or the “Company”)
Director/PDMR
Shareholding
Bioventix plc (BVXP), a UK company specialising in the
development and commercial supply of high-affinity monoclonal
antibodies for applications in clinical diagnostics, was notified
on 25 October 2019 of the following
transaction in its ordinary shares of 5
pence each (“Ordinary Shares”):
| Director |
Position |
Ordinary Shares
sold |
Sale price per
Ordinary Share |
Ordinary Shares
held subsequently |
Percentage of
issued share capital held subsequently |
| Ian Nicholson and Persons Closely
Associated |
Non-Executive Chairman |
2,500 |
3,158.67p |
15,500 |
0.3% |
Notification and
public disclosure of transactions by persons discharging managerial
responsibilities and persons closely associated with them
|
1. |
Details of the person
discharging managerial responsibilities / person closely
associated |
| a) |
Names |
Ian Nicholson (Non-Executive
Chairman) |
|
2. |
Reason for the
Notification |
| a) |
Position/status |
See 1(a) above |
| b) |
Initial notification/Amendment |
Initial notification |
| 3. |
Details of the
issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor |
| a) |
Name |
Bioventix plc |
| b) |
LEI |
213800225MHX7LZQY108 |
| 4. |
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted |
| a) |
Description of the Financial
instrument, type of instrument |
Ordinary shares of 5 pence
(“Ordinary Shares”) |
| Identification code |
GB00B4QVDF07 |
| b) |
Nature of the transaction |
Sale of Ordinary Shares |
| c) |
Price(s) and volume(s) |
| Price(s) |
Volume(s) |
| 3,158.67p |
2,500 |
|
| d) |
Aggregated
information:
· Aggregated volume
· Price |
See 4(c) |
| e) |
Date of the transaction |
25 October 2019 |
| f) |
Place of the transaction |
London Stock Exchange,
AIM Market (XLON) |
For further information please
contact:
Bioventix
plc
Peter Harrison |
Chief Executive Officer |
Tel: 01252 728 001 |
|
|
|
finnCap Ltd
Geoff Nash/Simon Hicks
Alice Lane |
Corporate Finance
ECM |
Tel: 020 7220 0500 |
About Bioventix plc:
Bioventix (www.bioventix.com) specialises in the development and
commercial supply of high-affinity monoclonal antibodies with a
primary focus on their application in clinical diagnostics, such as
in automated immunoassays used in blood testing. The antibodies
created at Bioventix are generated in sheep and are of particular
benefit where the target is present at low concentration and where
conventional monoclonal or polyclonal antibodies have failed to
produce a suitable reagent. Bioventix currently offers a portfolio
of antibodies to customers for both commercial use and R&D
purposes, for the diagnosis or monitoring of a broad range of
conditions, including heart disease, cancer, fertility, thyroid
function and drug abuse. Bioventix currently supplies antibody
products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its
shares are traded on AIM under the symbol BVXP.
The information communicated in this announcement contains
inside information for the purposes of Article 7 of the Market
Abuse Regulation (EU) No. 596/2014.